Cargando…

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy

BACKGROUND: Proprotein convertase subtilisin/kexin 9 (PCSK9) has been proposed as a novel target for coronary artery disease (CAD). Familial hypercholesterolemia (FH) is characterized by high prevalence of CAD and major cardiovascular events (MACEs). However, no data is available on the association...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Ye-Xuan, Jin, Jing-Lu, Sun, Di, Liu, Hui-Hui, Guo, Yuan-Lin, Wu, Na-Qiong, Xu, Rui-Xia, Zhu, Cheng-Gang, Dong, Qian, Sun, Jing, Li, Jian-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849213/ https://www.ncbi.nlm.nih.gov/pubmed/31711505 http://dx.doi.org/10.1186/s12967-019-2123-9

Ejemplares similares

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
por: Hwang, Hyeon Seok, et al.
Publicado: (2020)

NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study
por: Peng, Jia, et al.
Publicado: (2022)

Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency
por: Tarasov, Kirill, et al.
Publicado: (2014)

Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study
por: Peng, Jia, et al.
Publicado: (2020)

23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9
por: Li, Hui-hui, et al.
Publicado: (2019)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
por: Zhang, Yan, et al.
Publicado: (2014)

Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C
por: Li, Sha, et al.
Publicado: (2016)

PCSK9 inhibitors: A new era of lipid lowering therapy
por: Chaudhary, Rahul, et al.
Publicado: (2017)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

E670G PCSK9 polymorphism in HeFH & CAD with diabetes: is the bridge to personalized therapy within reach?
por: Alieva, Rano, et al.
Publicado: (2023)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
por: Peng, Jia, et al.
Publicado: (2021)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
por: Kosmas, Constantine E, et al.
Publicado: (2017)

Common Variable Immunodeficiency and Circulating T(FH)
por: Coraglia, Ana, et al.
Publicado: (2016)

Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
por: Khoshnejad, Makan, et al.
Publicado: (2019)

PCSK9 targets important for lipid metabolism
por: Schulz, Rainer, et al.
Publicado: (2017)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
por: Azar, Yara, et al.
Publicado: (2022)

GENetic characteristics and REsponse to lipid-lowering therapy in familial hypercholesterolemia: GENRE-FH study
por: Kim, Hyoeun, et al.
Publicado: (2020)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

PCSK 9 Inhibitors: A Short History and a New Era of Lipid-lowering Therapy
por: Hajar, Rachel
Publicado: (2019)

Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials
por: Luo, Jichang, et al.
Publicado: (2022)

Association between the rs615563 variant of PCSK9 gene and circulating lipids and Type 2 diabetes
por: Taghizadeh Jazdani, Samira, et al.
Publicado: (2021)

OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events
por: Hassan, Mohamed
Publicado: (2015)

Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials
por: Cao, Ye-Xuan, et al.
Publicado: (2018)

Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome
por: Yamashita, Satoshi, et al.
Publicado: (2023)

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

Sex difference in circulating PCSK9 and its clinical implications
por: Jia, Fang, et al.
Publicado: (2022)

PCSK9 as a therapeutic target for cardiovascular disease
por: Zhang, Pei-Ying
Publicado: (2017)

Efficacy and safety of PCSK9 inhibition in cardiovascular disease: A meta-analysis of 45 randomized controlled trials
por: Geng, Qiang, et al.
Publicado: (2022)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
por: Kohli, Payal, et al.
Publicado: (2016)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
por: Bandyopadhyay, Dhrubajyoti, et al.
Publicado: (2018)

Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
por: Zhang, Ruixing, et al.
Publicado: (2023)

Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats
por: Jia, Yan-Jun, et al.
Publicado: (2014)

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
por: Mayne, Janice, et al.
Publicado: (2013)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
por: Cai, Gaojun, et al.
Publicado: (2018)

Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
por: Ciccarelli, Giovanni, et al.
Publicado: (2018)

PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
por: Handelsman, Yehuda, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i5lmgcq1pivta773mb7in5odl2